INTRODUCTION
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by damage to myelin and axons. The prevalence is around 0.1-0.2% in northern Europe and the onset is typically in young adulthood. 1 MS is considered to be an autoimmune disease and dissection of its pathogenesis has led to better therapy, although in most cases broadly affecting the immune system with inherent long-term risks. Definition of risk genes and their subsequent functionality may reveal critical bottlenecks in the pathogenesis, with the aim to achieve more precise therapeutic strategies. Identification of genetic variants that influence susceptibility was until recently largely unsuccessful, owing to insufficient genome coverage and underpowered studies. However, two large genetic studies have now been published, which together identify 4100 genes that could influence MS susceptibility. 2, 3 Importantly, the genes should be considered as candidates as they have been identified based on proximity to disease-associated genetic variants, which potentially could regulate a distant gene or a set of genes. However, we have published data from rat studies showing that one or more natural variants in this locus do regulate interleukin-22-binding protein (IL-22BP) expression. Apart from rare examples, such as the tumor necrosis factor (TNF) receptor 1, 4 tyrosine kinase 2 5 and the IL-7 receptor, 6 the mechanism of influence of MS risk genes on disease have not been explored. One approach is to pursue this in experimental rodent models.
The most strongly MS-associated genetic variants outside the MHC complex include single-nucleotide polymorphisms near the IL-22 receptor alpha 2 (IL22RA2) that code for the IL-22BP. It was also identified as a candidate gene influencing an MS-like disease in rat and MS severity in a preceding study from our group. 7 Interestingly, gene variants within the IL-22 pathway are associated also with other inflammatory diseases. A variant near the ligand (IL22) is associated with inflammatory bowel disease, 8 a variant near a signaling receptor subunit (IL22RA1) associates to psoriasis, 9 and two variants near IL22RA2 are associated with celiac disease. 10 IL-22BP, which has been little studied, is known to be a soluble antagonist of IL-22 signaling. In vitro, it binds strongly to IL-22 and thereby blocks its interaction with the signaling IL-22 receptor (IL-22R). [11] [12] [13] In vivo, it is expressed by dendritic cells in the intestine and is needed there to control the proliferative effects of IL-22. 14 A recent study further defined the specific dendritic cell subsets in rats and mice and showed that the expression in human monocyte-derived DCs can be upregulated by retinoic acid. 15 IL-22R is a heterodimeric membrane-bound receptor consisting of the ubiquitously expressed IL10RB and IL22RA1, which is expressed mainly on tissues from barrier sites, such as skin, lungs and gut, and is generally thought to be absent from immune cells. 16 IL-22 signals to the IL-22R and the response, which is mainly pro-inflammatory, is important in the defense against microorganisms. The cytokine also acts in concert with other pro-inflammatory cytokines such as TNF and IL-17.
17
IL-22 is produced by cells from both the innate and adaptive arm of the immune system. 17 Notably, it is known as one of the signature cytokines of T helper 17 cells, which have been implicated as key pathogenic cells in MS and in the animal model experimental autoimmune encephalomyelitis (EAE). 18, 19 EAE disease course in Il22-deficient mice has been shown to be indistinguishable from wild-type mice. 20 However, owing to potential compensatory mechanisms during ontogeny, such an experiment does not exclude a role for IL-22 in EAE, which would require an inducible conditional gene deletion or downregulation.
We here study the potential role of IL-22BP in an experimental model for MS, myelin oligodendrocyte glycoprotein (MOG)-induced EAE using Il22ra2-deficient mice. Interestingly, Il22ra2 À / À mice displayed a slightly earlier disease onset, but a considerably less severe disease both with regard to clinical course and CNS inflammation. Temporal expression patterns of Il22, Il22ra1 and Il22ra2 in the wild-type lymphoid tissue were consistent with an initial pro-inflammatory disease-promoting role of the interplaying molecules. As with many cytokines dual actions are possible and our data is consistent with an initial systemic proinflammatory role of IL-22, but a beneficial disease downregulatory role within the CNS.
RESULTS AND DISCUSSION

Il22ra2
À / À mice have less severe EAE EAE was induced in Il22ra2 À / À mice and wild-type littermate controls by active immunization with MOG. Although the incidence and maximum score were similar between the groups, the knockout mice had a slightly earlier disease onset (Po0.05) (Figure 1c ; Table 1 ). However, they recovered faster after the peak of disease and had significantly better preserved motor function at the chronic stage compared with the control group ( Figure 1a) . Furthermore, the knockout mice entirely regained previously lost weight by day 25 post immunization, in contrast to their wild-type counterparts (Figure 1a ).
À / À mice display reduced CNS inflammation and demyelination In accordance with the functional disease score, spinal cords of the Il22ra2 À / À mice exhibited significantly reduced inflammation and demyelination at the chronic phase of EAE (Figure 1b) . Overall, brain pathology was less severe, which is a characteristic feature of this EAE-model, but still a trend consistent with the spinal cord data was observed.
The proportion of inflammatory monocytes in CNS infiltrates is reduced in Il22ra2 À / À mice Mononuclear cells were isolated from whole CNS during the chronic stage of EAE and characterized by flow cytometry. The number of mononuclear cells isolated from the inflamed CNS was significantly lower in the knockout mice (Figure 2a) . Furthermore, the relative proportion as well as the total cell number of monocytes/macrophages that were Ly6C þ , referred to as À / À mice (bottom row). Histopathological analyses were performed on day 32 post immunization. The sections were stained with hematoxylin and eosin (HE) and Kluever (KL) to reveal inflammatory infiltration and demyelination, respectively. Quantitative assessments of the histopathological analysis are presented as inflammatory index and demyelination score (n ¼ 6/5). (c) The day of onset was compared between the two groups (n ¼ 15/13, pooled from 3 experiments).
inflammatory monocytes, were significantly reduced in Il22ra2 À / À mice (Figure 2b ). There were no significant differences regarding neutrophils or IFNg þ , IL-17 þ or Foxp3 þ T cells (Figure 3 ). IL-22BP is expressed by antigen-presenting cells (APCs) in secondary lymphoid tissues and at barrier surfaces We assessed the homeostatic IL-22BP gene expression in a panel of tissues from the C57BL/6 mice used in our study. The highest levels were detected in secondary lymphoid tissues followed by the barrier surfaces, such as gut, skin and lungs (Figure 4a) . To learn what cell types are expressing IL-22BP in secondary lymphoid tissues, we sorted cells by fluorescence activated cell sorting based on the cell surface markers CD3, CD45R (B220), CD11b and CD11c. In both inguinal and mesenteric lymph nodes, IL-22BP expression was confined to CD11b þ cells with or without the surface marker CD11c. In mesenteric lymph nodes, we found expression also in CD103 þ DCs, commonly referred to as tolerogenic DCs (Figures 4c and d) .
By assessing the expression of Il22ra1, we could approximate the distribution of functional IL-22R complexes, and found these in the same barrier surfaces as above as well as in parenchymal organs where IL-22BP is absent. In contrast to IL-22BP, no IL-22R was present in secondary lymphoid tissues (Figure 4a ). The presence of IL-22BP protein in inguinal lymph nodes was also confirmed using the immunofluorescence (IF) technique ( Figure 4b ).
À / À mice have an unaltered homeostatic immune compartment To address the concern of alterations in immune system development in constitutive knockout strains, we did a comprehensive survey of the cell proportions in inguinal lymph nodes and spleen. We found no conspicuous differences compared with wild-type littermates ( Table 2 ). The total cell number in the respective organ was also similar (data not shown) as well as serum levels of immunoglobulin (Ig)G, IgM, IgA and IgE ( Figure 5 ).
Il22, Il22ra1 and Il22ra2 transcripts are altered after EAE induction We investigated the expression of Il22ra2 and related transcripts by quantitative PCR in the lymph nodes draining the site of EAE immunization, in inflamed spinal cord and in infiltrating mononuclear cells isolated from whole CNS. At baseline, there is no Il22 messenger RNA in the inguinal lymph nodes but after immunization there is a clear expression. Similarly Il22ra1 is absent in inguinal lymph nodes at baseline but is upregulated upon immunization. Il22ra2 expression is reduced to approximately one third after immunzation (Figure 6a ).
Il22ra1 or Il22ra2 messenger RNA was not detected in mononuclear cells isolated from the CNS at the chronic stage (day 24) of EAE, but Il22 was present at high levels in both Il22ra2 À / À and Immunofluorescence performed on the cross-sections of paraffin-embedded naive wild-type inguinal lymph nodes to demonstrate IL-22BP (green), whereby cell nuclei were visualized using 4' ,6-diamidino-2-phenylindole (DAPI) (blue). Mesenteric (c) and inguinal (d) lymph node cells (n ¼ 6, pooled) were sorted by fluorescence activated cell sorting and IL-22BP mRNA was quantified in the specified populations.
IL22RA2 contributes to a more severe EAE H Laaksonen et al wild-type mice. However, in perfused and homogenized spinal cord, IL-22 was barely detectable at baseline or chronic stage EAE. Il22ra1 was expressed in the inflamed CNS but at lower levels compared with baseline. Il22ra2 was detected at similar levels at the two time points and was, as expected, absent in the Il22ra2 À / À mice (Figure 6b ).
T cells from Il22ra2
À / À and wild-type mice are phenotypically similar in the priming phase We investigated whether the earlier onset of EAE symptoms in Il22ra2 À / À mice is caused by differences in T-cell priming. Seven days after immunization, inguinal lymph nodes cells from Il22ra2 À / À and wild-type mice were analyzed by flow cytometry. No differences were observed regarding the proportion or total number of IFNg þ , IL-17 þ or Foxp3 þ T cells. Similarly, no differences were observed regarding the proportion or total number of CD44 þ CD62L À effector T cells (Figure 7a ). The total number of inguinal lymph node cells as well as the proliferative response of these, when incubated with MOG, were both similar (Figures 7b and c) .
This report provides data on how the MS risk gene IL22RA2 can influence MS-like disease. We here show that mice with constitutive deletion of Il22ra2 (IL-22BP) have less severe EAE. 
IL22RA2 contributes to a more severe EAE H Laaksonen et al
We did not observe any difference in T-cell priming or polarization in the periphery, but in the target tissue there was less infiltration of Ly6C þ inflammatory monocytes; cells that have been shown to have an important pathogenic role in the EAE model. 21 , 22 We further demonstrate dynamics in the expression of IL-22, Il-22R and IL-22BP in the draining lymph node at T-cell priming and in the CNS after disease onset. We show that IL-22BP is expressed in lymph nodes during homeostasis by APCs. Considering the role of IL-22BP as a regulator of IL-22 signaling, our data suggest that, in the context of neuroinflammation, IL-22BP has a paradoxical proinflammatory effect. The data are in line with those we presented before, in which a congenic rat strain with low expression of Il-22BP, displayed less severe disease. 7 Experiments in human samples are ongoing, but have so far been hampered by the near absence of IL-22BP messenger RNA in blood cells (data not shown).
Although our data are consistent with a harmful role of IL-22BP, either in the extreme condition as here with a complete selective gene deletion or by natural variants affecting its levels, such as in the rat 7 and potentially humans, the exact mechanisms for such an effect is still unclear.
We primarily consider a scenario where insufficient levels of IL-22BP lead to higher availability in the CNS of IL-22, where it could act to decrease inflammation and enhance repair. Although regarded primarily as a pro-inflammatory cytokine, there are several examples of a beneficial role in tissue repair, in the liver and the intestine. 17 If so, the situation is similar to TNF and expression of its soluble receptor. TNF apparently has a paradoxical role in downregulating inflammation in MS and EAE; blockage of TNF worsens MS 23, 24 and MS-risk allelic variants of the TNF receptor gene lead to higher levels of soluble forms of the receptor, which block TNF signaling. 4 However, there are alternative explanations. One could consider the possibility of IL-22BP acting not only as a blocking protein, but perhaps also as a 'carrier protein', which potentially could increase the action of IL-22 in the CNS. This would be similar to the mechanisms for the IL-7 receptor, where circulating soluble receptors increase inflammation. 6 We regard this explanation as less likely in view of the very high binding affinity of IL-22BP to IL-22.
13,25
We started our study by assessing the expression of IL-22BP in a number of organs relevant for the field of autoimmunity in C57BL/ 6 mice and found the highest expression in lymph nodes including Peyer's patches. This is in line with the findings of Martin et al., 15 although they described even higher expression in the spleen, which in our mice expressed only moderate amounts. Expression in gut, lungs and skin is generally reported in the literature, which we also observed. The cellular source has been inconsistently defined in the literature, but recent reports focusing on mucosal immunity established it as dendritic cells. 14, 15 We found CD11b to be the cell surface marker that best predicted IL-22BP gene expression in mesenteric and skin-draining lymph nodes, which we interpret as APCs. We further confirm the presence of IL-22BP protein by the IF-labeling technique on inguinal lymph nodes, which gave a staining pattern similar to what would be expected of an APC-associated product. Double staining with CD11b has so far not been possible owing to incompatible staining protocols. We could also detect low amounts of IL-22BP transcripts in the CNS, as previously reported by Dumoutier et al.
12
The expression of IL-22, the only known ligand for IL-22BP, was strongly upregulated in the lymph nodes draining the site of EAE immunization as well as by infiltrating mononuclear cells in the inflamed CNS. IL-22 has been found in the CNS in both EAE and MS. 20, 26 The IL-22R is generally thought to be absent from hematopoietic cells and this may be true during homeostasis. We found no expression in the inguinal lymph nodes at baseline but after immunization transcripts for IL-22R (Il22ra1) were present, which has also been observed in a study on the related model experimental autoimmune uveitis. 27 We have not been able to get a specific western blot signal with commercial antibodies to confirm this on the protein level. We found downregulation IL22RA2 contributes to a more severe EAE H Laaksonen et al of IL-22BP expression in lymph nodes draining the site of EAE immunization. Huber et al. 14 showed that after sensing of tissue damage via the inflammasome, in the colonic mucosa, IL-22BP expression is downregulated in an IL-18-dependent manner. The same mechanism could be operating in draining lymph nodes after immunization. Kreymborg et al. 20 showed that IL-22
mice have an EAE disease course that is indistinguishable from wild-type controls. In the setting of IL-22BP deficiency there is contrary to the aforementioned study, excess of free IL-22. Direct treatment with IL-22 has been used in experimental autoimmune uveitis with the results of reduced disease severity if administered before disease onset, 27 data which would be in line with our speculations on the role of IL-22 above.
Although the CNS was less severely damaged in the Il22ra2 À / À mice, they had an earlier onset of disease. We have found no explanation for this when studying the early events of T-cell priming but other, perhaps more subtle differences, not caught in our assays may have led to earlier priming of autoaggressive T cells in the regional lymph nodes, in line with a potential pro-inflammatory role in the systemic compartment.
As part of the International MS genetics consortium, we identified the single-nucleotide polymorphism rs17066096, intergenically located near IL22RA2, to be associated with MS susceptibility in the 2011 genome-wide association study as well as in our recently published study using the immunochip platform and independent samples. 2, 3 It is not yet known whether and how the human gene variation affects expression of the molecule. On the basis of our experimental data, an increased expression/action would be postulated.
In conclusion, this report provides data on the MS risk gene IL22RA2 in the context of neuroinflammation. We are working on furthering our understanding of the precise mechanisms of the reduced disease severity in Il22ra2 À / À mice, including the possibility of identifying alternative ligands for IL-22BP. We IL22RA2 contributes to a more severe EAE H Laaksonen et al suggest that neutralization of IL-22BP to treat MS relapses is a therapeutic strategy worthy of further exploration. Our data are also important in general for any attempts to intervene in the IL-22 pathway in inflammatory disease in general, including MS. The data are to be taken into account in clinical trials of manipulating this cytokine pathway to avoid unexpected deleterious effects, as happened with blocking of TNF in MS.
MATERIALS AND METHODS
Ethics statement
All procedures performed on animals in this study were approved by the local ethics committee (Stockholms norra djurfö rsö ksetiska nämnd).
Real-time PCR
Total RNA from cells and tissues was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) with on-column digestion of genomic DNA using the RNase-free DNase set (Qiagen). The iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) was used to prepare complementary DNA. Real-time reverse transcriptase-PCR was performed on CFX384 Real-Time system machines (Bio-Rad) using IQ SYBR green Supermix (Bio-Rad), and data analysis was done manually using the dCT-method. Primers used were:
Fluorescence activated cell sorting 
Mice
The mouse strain used for this research project, B6N.129S5-Il22ra2 tm1Lex / Mmcd, identification number 032407-UCD, was obtained from the Mutant Mouse Regional Resource Center, a NCRR-NIH funded strain repository, and was donated to the MMRRC by Genentech Inc (San Fransisco, CA, USA). Male mice between the age of 8 and 16 weeks were used for all experiments. Age-matched wild-type littermates were used as controls. Mice were bred and maintained in a specific pathogen-free facility at the Karolinska University Hospital (Stockholm, Sweden), in polystyrene cages with aspen wood shavings, free access to water and standard rodent chow.
Enzyme-linked immunosorbent assay
Serum was prepared from blood collected from an orbital socket of newly killed mice. The concentration of IgG, IgM and IgA was determined using Ready-SET-go ELISA kits (eBioscience, San Diego, CA, USA) and IgE using ELISA Max Deluxe Set (BioLegend).
EAE
Mice were injected subcutaneously at the tail base with 50 mg of myelin oligodendrocyte glycoprotein emulsified in Freunds adjuvant (SigmaAldrich, St Louis, MO, USA) supplemented with non-viable M. tuberculosis H37 RA (Difco laboratories, Franklin Lakes, NJ, USA). At immunization and 2 days later, the mice were injected intraperitoneally with 200 ng of pertussis toxin (Sigma-Aldrich). Animals were weighed and observed daily. Clinical signs were assessed as follows: 0, no paralysis; 1, tail paralysis; 2, hind limb paresis 3, hind limb paralysis; 4, hind and front limb paralysis; 5, dead.
Histopathology and IF
On day 32 post immunization, mice were euthanized using CO 2 and perfused with phosphate-buffered saline followed by 4% paraformaldehyde (PFA) via the left ventricle. Paraformaldehyde-fixed paraffinembedded brain and spinal cord cross-sections (3-5 mm thick) were dewaxed in xylol, rehydrated and stained with hematoxylin and eosin and Luxol Fast Blue (Kluever, KL) to assess inflammation and demyelination, respectively. The inflammatory index and demyelination score were calculated as previously described 28 on an average of 10 complete spinal cord cross-sections.
For IF, brain and spinal cord paraffin sections were treated as previously described. 29 Endogenous peroxidase was blocked by incubation in methanol with 0.02% H 2 O 2 for 30 min at room temperature. Rehydration to distilled water followed through 95, 70 and 50% ethanol dilution series. Antigen retrieval was performed with citrate buffer pH 6.2 by warming for 1 h in a steamer device (Braun, Kronberg, Germany). Sections were incubated in 0.1 M phosphate-buffered saline containing 10% fetal calf serum for 30 min before incubation with primary antibody on 4 1C, overnight. Primary antibodies used for targeting IL-22BP were anti-Il22ra2 at 1:200 (FL-230, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-IL22RA2 at 1:100 (HPA030582, Sigma-Aldrich). Alexa-Fluor 488 conjugated secondary antibody at 1:1000 (Invitrogen, Carlsbad, CA, USA) was applied the next day for 1 h at room temperature. After washing, the sections were mounted with ProLong Gold Antifade Reagent (Life Technologies, Carlsbad, CA, USA) with 4',6-diamidino-2-phenylindole nuclear stain. Control sections were incubated in absence of the primary antibody. Histopatological and IF analysis and imaging were performed on Reichert Polyvar 2 and confocal microscope (Zeiss LSM700, Oberkochen, Germany). Presented images are two-dimensional depictions of 10-mm-thick z-stacks.
Isolation of CNS-infiltrating mononuclear cells
Mice were perfused with sterile phosphate-buffered saline (Sigma-Aldrich) containing 2500 lE À 1 heparin (Orifarm, Odense, Denmark). Brain and whole-spinal cord were dissected and homogenized in a solution of 50% percoll (Sigma-Aldrich) in Hank's balanced salt solution containing 50 U ml À 1 Dnase I (Roche, Basel, Switzerland) using a glass homogenizer (Kimble-Chase, Vineland, NJ, USA). A 63% and 30% percoll solution was added as underlay and overlay, respectively, followed by centrifugation at 1000 g for 20 min. Mononuclear cells were collected and analyzed by flow cytometry. Total cell numbers were approximated by fixed time acquisition in the flow cytometer.
Flow cytometry
